Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
April 23 2018 - 9:30AM
Key Highlights:
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome
biopharmaceutical company focused on developing and commercializing
orally delivered targeted polyclonal antibodies for the treatment
of inflammatory mediated and infectious diseases, is today pleased
to announce the sales results of its commercially available,
over-the-counter gastrointestinal and digestive health supplement
Travelan®, for the third fiscal quarter ending
March 31, 2018.
Travelan®’s robust sales growth continued
throughout the third quarter both in Australia and the US, with
combined sales to March 31, 2018 reaching AUD$1.37M marking a 40%
increase on the same period last year.
The third quarter saw US Travelan® sales surge
ahead, achieving AUD$166K and marking a +95% increase compared to
the AUD$85K sales figure achieved for the same period last year.
This resulted in year-to-date (YTD) US sales of AUD$501K for
nine-months ended March 31, 2018, compared to AUD$180K sales for
the same period last year. These figures demonstrate that Immuron
is on track to more than double its 2017 sales of Travelan® in the
US market by the end of the 2018 fiscal year.
In Australia, Travelan® continues its sales
momentum achieving AUD$863K for the nine-months ended March 31,
2018, representing a +9% increase on the same period last year.
The healthy growth of Travelan® sales can be
attributed to our continued trade marketing program within major
Australian pharmacies and our distribution in the USA through over
193 Passport Health Travel Clinics. An additional 39 clinics within
the Passport Health Travel network will commence distribution of
Travelan® in the fourth quarter, providing even further
opportunities to bolster US sales.
Immuron’s Marketing Manager Mr. David
Montgomery, said,
“In addition to the growing distribution of
Travelan®, the ground-breaking US Department of Defense (DoD)
research report which was announced in January 2018 has generated
excitement within the investor market and the travel medicine
community.
"The primary goal of this US DoD program was to
investigate Travelan®’s immunological reactivity with pathogenic
bacteria including Campylobacter, Enterotoxigenic E-coli and
Shigella.
"The tested bacterial isolates originated from
the Armed Forces Research Institute of Medical Sciences (AFRIMS) in
Bangkok, Thailand an overseas laboratory of the Walter Reed Army
Institute of Research (WRAIR) library of infectious diseases. The
pathogenic bacteria were retrieved from infected personnel deployed
in Bhutan, Cambodia, Nepal and Thailand over a 20-year period.
"The research findings have provided further
data to build on existing clinical trial results for Travelan® and
have provided us with a powerful message to take to the market that
the antibodies in Travelan® were able to bind and reactive to all
180 strains of bacteria tested demonstrating the broad spectrum
antimicrobial potential of the product.”
COMPANY CONTACT: Jerry
KanellosChief Executive Officer (Interim)Ph: +61 (0)3 9824
5254jerrykanellos@immuron.com |
USA INVESTOR RELATIONS: Jon
CunninghamRedChip Companies, Inc.US Ph: +1 (407) 644 4256,
(ext. 107)jon@redchip.com |
AUS INVESTOR RELATIONS: Peter
TaylorNWR CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
ABOUT IMMURON:
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is an
Australian microbiome biopharmaceutical company focused on
developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated and
infectious diseases. Immuron has a unique and safe technology
platform that enables a shorter development therapeutic cycle. The
Company currently markets and sells Travelan® for the prevention of
Travelers’ Diarrhea and its lead clinical candidate, IMM-124E, is
in Phase II clinical trials for Non-Alcoholic
Steatohepatitis (NASH), Severe Alcoholic
Hepatitis (SAH) and Pediatric Non-Alcoholic Fatty
Liver Disease (NAFLD). Immuron’s second clinical
stage asset, IMM-529, is targeting Clostridium difficile
Infections (CDI). These products together with the
Company’s other preclinical immunotherapy pipeline products
targeting immune-related diseases currently under development, will
meet a large unmet need in the global immunotherapy market.
For more information visit:
http://www.immuron.com
About Travelan®
Travelan® is an orally administered passive
immunotherapy that prophylactically reduces the likelihood of
contracting travellers’ diarrhoea. Travelan® is a highly purified
tabletised preparation of hyper immune bovine antibodies and other
factors, which when taken with meals bind to diarrhoea-causing
bacteria and prevent colonization and the pathology associated with
travellers’ diarrhoea. In Australia Travelan® is approved by the
Therapeutic Goods Administration (TGA) as a listed medicine on the
Australian Register of Therapeutic Goods (AUST L106709) and is
indicated to reduce the risk of travellers’ diarrhoea and
associated symptoms of minor gastrointestinal disorders. In the USA
Travelan® is sold as a dietary supplement in accordance with
section 403 (r)(6) of the Federal Drug Administration (FDA).
FORWARD-LOOKING STATEMENTS:
This press release may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by
law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024